Page last updated: 2024-11-13

zilascorb

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

zilascorb: RN given refers to unlabeled parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54682464
CHEMBL ID2221292
SCHEMBL ID62540
MeSH IDM0192335

Synonyms (18)

Synonym
tumor necrosisfactor-alpha (tnf-.a.) & sodium 5,6-benzylidene-l-ascorbate
sba & tnf-.a.
(4's,5r)-3,4-dihydroxy-5-(2'-phenyl-[1',3']dioxolan-4'-yl)-5h-furan-2-one
(2r)-3,4-dihydroxy-2-[(4s)-2-phenyl-1,3-dioxolan-4-yl]-2h-furan-5-one
zilascorb
l-ascorbic acid, 5,6-o-(phenylmethylene)-
sodium-5,6-o-benzylidene ascorbate
5,6-o-benzylidene-l-ascorbic acid
20664-60-2
t544m6z94a ,
unii-t544m6z94a
SCHEMBL62540
SWTGJCNCBUCXSS-ISUZDFFFSA-N
CHEMBL2221292
l-ascorbic acid, 5,6-o-benzylidene-
DTXSID50942865
5,6-o-benzylidenehex-1-enofuranos-3-ulosato(2-)
Q27289686

Research Excerpts

Overview

Zilascorb(2H) is a benzaldehyde derivative giving rise to strong protein synthesis inhibition.

ExcerptReferenceRelevance
"Zilascorb(2H) is a benzaldehyde derivative giving rise to strong protein synthesis inhibition. "( Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma.
Aamdal, S; Gullaksen, N; Ingvar, C; Mette, E; Osmundsen, K; Semb, KA, 1998
)
3.19

Bioavailability

ExcerptReferenceRelevance
" Zilascorb(2H) in tablet formulation had a bioavailability of 32%, was quickly absorbed and slowly eliminated."( Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation.
Aamdal, S; Bibow, K; Fodstad, O; Klem, B; Osmundsen, K; Semb, KA, 1997
)
2.65
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's0 (0.00)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.41%)5.53%
Reviews2 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (89.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]